Role of TGF-β on cardiac structural and electrical remodeling by Ramos-Mondragón, Roberto et al.
© 2008 Ramos-Mondragón et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2008:4(6) 1289–1300 1289
REVIEW
Role of TGF-β on cardiac structural 
and electrical remodeling
Roberto Ramos-Mondragón
Carlos A Galindo
Guillermo Avila
Departamento de Bioquímica, 
Cinvestav-IPN, México
Correspondence: Guillermo Avila
Departamento de Bioquímica, 
Cinvestav-IPN, AP 14-740, México, 
DF 07000, México
Tel +52 55 5747 3952
Fax +52 55 5747 3391
Email gavila@cinvestav.mx
Abstract: The type β transforming growth factors (TGF-βs) are involved in a number of human 
diseases, including heart failure and myocardial arrhythmias. In fact, during the last 20 years 
numerous studies have demonstrated that TGF-β affects the architecture of the heart under both 
normal and pathological conditions. Moreover, TGF-β signaling is currently under investigation, 
with the aim of discovering potential therapeutic roles in human disease. In contrast, only few 
studies have investigated whether TGF-β affects electrophysiological properties of the heart. 
This fact is surprising since electrical remodeling represents an important substrate for cardiac 
disease. This review discusses the potential role of TGF-β on cardiac excitation-contraction (EC) 
coupling, action potentials, and ion channels. We also discuss the effects of TGF-β on cardiac 
development and disease from structural and electrophysiological points of view.
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Introduction
The superfamily of type β transforming growth factors (TGF-β) includes TGF-β1, 
TGF-β2, and TGF-β3, bone morphogenetic proteins (BMPs), growth differentiation 
factors (GDFs), activins, and inhibins. At least 35 members of this superfamily have 
been discovered in vertebrates. These factors regulate a diverse array of cellular 
processes, including tissue development and repair. Their effects are mediated by 
binding to two types of functional receptors (TBRI and TBRII), which are single-pass 
transmembrane serine/threonine kinases that phosphorylate speciﬁ  c signal-transducing 
molecules termed Smads (Figure 1). Activated Smads can be translocated into 
the nucleus, bind to the DNA, and regulate the transcription of speciﬁ  c genes. 
The TGF-βs bind to and activate the type II receptor (TBRII), which in turn binds to 
and phosphorylates the type I receptor (TBRI). This yields to formation of a tetrameric 
complex of proteins, formed by two TBRIs and two TBRIIs. Once activated, the 
TBRI phosphorylates the C-terminus of receptor-associated Smads (or R-Smads, eg, 
Smad 3); see Chang and colleagues (2002) for an excellent and comprehensive review 
regarding signaling pathways and in vivo effects of TGF-β.
Even though C-terminal phosphorylation is the key event in Smads activation, other 
kinase pathways also regulate the Smad signaling. For example, both tyrosine kinase 
receptors to epidermal growth factor (EGF) and hepatocyte growth factor phosphorylate 
Smad2, and induce its nuclear translocation (de Caestecker et al 1998). In fact, the 
activation of Smads can be also induced by at least the following signaling pathways: 
the Erk mitogen-activated protein kinase (MAPK) and the Ca2+/calmodulin-dependent 
protein kinase II (CamKII). Thus, similar to other signaling pathways, the TGF-β 
signaling exhibits cross-talk with a number of second messengers. Moreover, other 
molecules apart from Smad proteins interact with and regulate the activaty of TBRs, 
without apparent direct activation of Smads (eg, FK-506 binding protein). Finally, 
the activated receptor can also activate non-Smad signaling pathways, such as PP2A, 
Erk, JNK, PI3K, and p38MAPK (Derynck and Zhang YE 2003).Vascular Health and Risk Management 2008:4(6) 1290
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The TGF-β signaling is involved in a number of 
human pathologies, including lung fibrosis (Willis and 
Borok 2007), renal and liver injury (Breitkopf et al 2005; 
Böttinger 2007), Alzheimer (Masliah et al 2001), cancer 
(Roberts and Wakeﬁ  eld 2003), and cardiac remodeling 
(Bujak and Frangogiannis 2007; Burstein and Nattel 2008). 
The role of TGF-β on cardiac pathophysiology began to 
be elucidated ∼20 years ago by Thompson and colleagues 
(1988). Basically, what they found was that ventricular 
myocytes from the infarcted myocardium overexpresses 
TGF-β1 protein and mRNA. Soon thereafter, Potts and 
Runyan (1989) suggested a role for TGF-β signaling in 
promoting development of the heart. To this date, a great 
deal of information regarding to the effects of TGF-β on 
cardiac architecture has been accumulated. In fact, signiﬁ  -
cant efforts are currently been made to discover potential 
therapeutic roles for TGF-β signaling in cardiac pathology 
(Narine et al 2004; Ng et al 2004; Li et al 2005; Liao 2005; 
Okada et al 2005).
Role of TGF-β in cardiac 
development
The TGF-β signaling is essential to epithelial–mesenchymal 
transformation (EMT). This is an embryonic phenomenon 
that determines formation of cardiac valves and the septa. 
Speciﬁ  cally, the EMT involves endothelial cells that migrate 
into an expanded extracellular matrix (or the cardiac jelly) 
where they proliferate and differentiate into mesenchymal 
cells. Subsequently, locally expanded swellings of cardiac 
jelly and mesenchymal cells form what is known as 
endocardial cushion tissue, which undergoes an extensive 
remodeling from bulbous swellings to eventual thinly tapered 
heart valves (Nakajima et al 2000).
A number of studies show that the TGF-β superfamily 
signaling is essential for heart development. For example, 
TGF-β1, -β2, and -β3, as well as BMP-2, -4, -6, and -7, are 
all expressed at speciﬁ  c regions and stages of development 
of the immature heart. In addition, several receptors (ALK2, 
ALK3, and ALK5) and downstream molecules (Smad5 and 
Smad6) are important in cardiac morphogenesis. Moreover, 
BMP-2-null mice either do not have a heart, or develop a 
very retarded and malformed heart, mice carrying mutations 
in BMP-5 or -7 die before birth with multiple defects in 
heart development, and mice deﬁ  cient in BMP-6 or -7 have 
delayed cardiac cushion formation, which results in subse-
quent valve and septation defects, as well as a premature 
death due to heart failure (Chang et al 2002). Isoforms of the 
TGF-β subfamily are also important for heart development. 
For example, speciﬁ  c antibodies against the corresponding 
receptors inhibit EMT (Potts and Runyan 1989; Boyer et al 
1999; Brown et al 1999), the heart of TGF-β2-null mouse 
embryos have speciﬁ  c defects in the development of the 
valves and septa (Sandford et al 1997), and both TGF-β2 and 
TGF-β3 are critical to the initiation and regulation of EMT 
(Chang et al 2002). Thus, several TGF-βs are required to 
achieve proper valve morphogenesis, and according to this, 
there are numerous of non-compensated functions between 
the three different isoforms of the TGF-β subfamily. For 
example, TGF-β2 null-mice exhibit multiple defects that 
are not overlapping with TGF-β1- and TGF-β3-null mice 
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Figure 1 TGF-β1 and its general mechanism of action. Binding of TGF-β1 with its receptor (TGF-βR) activates intracellular signaling proteins termed Smads receptors (R-Smads, 
eg, Smad3), which are translocated into the nucleus following interaction with co-activator proteins termed co-Smads. Once in the nucleus, the Smads bind to the DNA and 
regulate transcription of speciﬁ  c genes. Inhibitory Smads, like Smad 6 and 7 prevent activation of R-Smads, by competitively inhibiting either its activation by the receptor, or 
its association with Co-Smads. Smads independent signaling pathways can also contribute to diversify responses to TGF-β1 (eg, MAPK kinases, and Rho GTPases).Vascular Health and Risk Management 2008:4(6) 1291
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(Sandford et al 1997), and TGF-β2 promotes cardiac cushion 
formation by activating a unique set of downstream media-
tors (ie binding to a third type receptor or TBRIII, which in 
turn modiﬁ  es the functional TBRI-TBRII signaling complex 
(Brown et al 1999). Moreover, TGF-β2 and TGF-β3 exert 
distinct effects in EMT during valve formation (Boyer et al 
1999), and TGF-β1 plays a critical role in adult cardiac 
structural remodeling (Bujak and Frangogiannis 2007; 
Burstein and Nattel 2008). Below we describe the major 
alterations associated to cardiac remodeling, as well as the 
corresponding TGF-β effects.
Structural remodeling of the 
ventricle
Cardiac structural remodeling stands for several 
morphological changes that can be induced by the following 
physiological and pathophysiological factors, cytokine 
and neurohumoral stimuli, hemodynamic load, an altered 
function of mutant proteins, and a loss of contractile mass 
from prior infarction (Figure 2). The involved changes 
include alterations on the expression levels of structural 
proteins, as well as an increase on the following parameters: 
proliferation rate of ﬁ  broblast, deposition of extracellular 
matrix (ECM) constituents or fibrosis, and the size of 
cardiac myocytes or hypertrophy. Ventricular hypertrophy 
accompanies many forms of heart disease, such as ischemic 
disease, hypertension, heart failure, and valvular disease. 
Initially, hypertrophy helps the heart to meet the needs of the 
body (compensated hypertrophy). However, in response to a 
more severe, or prolonged stimuli, the hypertrophy becomes 
inadequate (decompensated hypertrophy), and contributes 
per se to the genesis of ischemia, arrhythmia, and heart failure 
(see the vicious circles that are indicated with gray arrows 
in Figure 2,). Some alterations in gene expression that are 
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Figure 2 Role of TGF-β on ventricular remodeling. Certain human diseases provoke cardiac work-overload, which in turn promotes several changes known as structural and 
electrical remodeling. Initially, these changes help the heart to meet the needs of the body, by means of optimizing cardiac output (acute remodeling). However, in response to 
prolonged stimuli the remodeling becomes inadequate and contributes per se to cardiac dysfunction (vicious circles indicated by gray arrows). Interestingly, work-overload also 
increases the expression levels of TGF-β1. In fact, TGF-β1 per se reproduces most of the hallmarks associated to structural remodeling (asterisks), including its own overexpres-
sion. TGF-β1 may also provoke electrical remodeling (dotted arrow), but the corresponding effects have not been thoroughly investigated.Vascular Health and Risk Management 2008:4(6) 1292
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involved in hypertrophy are switching from adult α-myosin 
heavy chain (α-MHC) to fetal β-myosin heavy chain 
(β-MHC), and reexpression of skeletal α-actin. Altogether, 
this pattern of gene expression mimics that seen during 
embryonic development and is thus called re-induction of 
the “fetal-gene program”. Thus, hypertrophy seems to be 
a programmed reversion toward a more fetal phenotype 
(Bers 2001; Katz 2002; Hill 2003).
Activation of the renin–angiotensin system (RAS) has 
been implicated in the generation of cardiac remodeling 
(hypertrophy and ﬁ  brosis). In fact, inhi bition of angiotensin II 
(or Ang II, the effector molecule of the RAS), by angiotensin-
converting enzyme (ACE) inhibitors or Ang II type 1 (AT1) 
receptor antagonists prevents structural remodeling of the ven-
tricle. Interestingly, while Ang II directly promotes growth in 
neonatal cells, it does not in adult cardiomyocytes, suggesting 
Ang II indirectly promotes hypertrophy. In fact, Ang II exerts 
its in vivo proﬁ  brotic and hypertrophic effects by increasing 
the expression levels of TGF-β1 (Rosenkranz 2004).
Role of TGF-β in structural 
remodeling of the ventricle
The proposed role for TGF-β1 in cardiac disease is 
illustrated in Figure 2. Both neonatal and adult cardio-
myocytes synthesize and release the three mammalian 
isoforms of the TGF-β subfamily (ie, TGF-β1, TGF-β2, and 
TGF-β3), although it is the TGF-β1 and TGF-β3 isoforms 
that predominate (Long 1996). The cardiac myocytes increase 
expression levels of TGF-β1 in response to myocardial stress 
in an animal model of myocardial infarction (Thompson et al 
1988). Accordingly, expression levels of TGF-β1 mRNA 
are also increased in left ventricular myocardium of patients 
with either idiopathic hypertrophic cardiomyopathy (Li et al 
1997) or dilated cardiomyopathy (Pauschinger et al 1999), 
as well as in animal models of norepinephrine-induced 
hypertrophy (Bhambi and Eghbali 1991), progressive coro-
nary artery occlusion (Wünsch et al 1991), and pressure over-
load (Villarreal and Dillmann 1992). In both experimental 
models and humans TGF-β1 is particularly overexpressed 
in myocardium during transition from stable hypertrophy to 
heart failure. Thus, TGF-β1 is considered an essential media-
tor of cardiac adaptation to work overload. In fact, TGF-β1 
represents one of the few markers that discriminate between 
compensated and decompensated hypertrophy (in addition to 
increased collagen content) (Rosenkranz 2004).
Perhaps more importantly, TGF-β1 reproduces most of the 
hallmarks seen in structural remodeling (Figure 2, asterisks). 
Speciﬁ  cally, TGF-β1 induces expression levels of ECM 
constituents by cardiac fibroblasts (ie, fibrillar collagen, 
fibronectin, and proteoglycans), self-amplifies its own 
expression in both cardiac myocytes and ﬁ  broblast (Desmouliére 
et al 1993; Long 1996), stimulates the proliferation of ﬁ  broblasts 
and their phenotypic conversion to myoﬁ  broblasts (Sappino 
et al 1990; Walker et al 2004) and provokes “fetal” contractile 
protein gene expression in cardiomyocytes (Parker et al 1990). 
Additionally, TGF-β1 mediates the cardiac hypertrophy 
induced by Ang II (Schultz Jel et al 2002), overexpression 
of TGF-β1 in transgenic mice results in hypertrophic growth 
of ventricular myocytes (Nakajima et al 2000), heterozygous 
TGF-β1 (±)-deﬁ  cient mice exhibit decreased ﬁ  brosis of the 
aging heart (Brooks and Conrad 2000) and functional blockage 
of TGF-β1 signaling in vivo by neutralizing antibodies prevents 
myocardial ﬁ  brosis and dysfunction in pressure overloaded 
hearts (Kuwahara et al 2002).
Structural remodeling of the atrium
Atrial remodeling, which stands for “any persistent change 
in atrial structure or function”, promotes the occurrence 
or maintenance of atrial ﬁ  brillation (AF), by acting on the 
fundamental mechanisms of the arrhythmia (Thompson 
et al 1988). Accordingly, AF can be induced by several 
physiological and artificial stimuli (Figure 3), such as 
heart failure (Li et al 1999; Lee et al 2006), senescence 
(Anyukhovsky et al 2002; Hayashi et al 2002), atrial 
dilatation (Eckstein et al 2008), and rapid atrial rate of 
stimulation (Morillo et al 1995). Structural remodeling 
and in particular interstitial ﬁ  brosis represents the major 
promoter of AF. This is because ﬁ  brosis provokes disrup-
tion of electrical conduction among adjacent myocytes, due 
to an increased deposition of extracellular matrix, which 
disrupts the normal myocardial ultrastructure. In fact, trans-
genic mice overexpressing cardiac TGF-β1 develop atrial 
ﬁ  brosis, heterogeneous conduction, and AF (Verheule et al 
2004). Additionally to atrial ﬁ  brosis, myocyte loss by either 
apoptosis or necrosis accompanies AF (Burstein and Nattel 
recently reviewed structural alterations associated to AF 
(Burstein and Nattel 2008)).
The cellular mechanisms that underlie cardiac ﬁ  brosis 
are similar to ﬁ  brosis in other epithelial organs. Accordingly, 
ﬁ  broblasts represent the principal cellular mediators of cardiac 
ﬁ  brosis. The increased number of these cells was initially 
thought to originate from proliferation of resident ﬁ  broblasts, 
bone marrow cells, and epithelial cells (derived through EMT). 
More recently, cardiac ﬁ  broblasts were also shown to be 
derived from endothelial cells, via endothelial–mesenchymal 
transformation (EndMT) (Kisseleva and Brenner 2008).Vascular Health and Risk Management 2008:4(6) 1293
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Role of TGF-β in structural 
remodeling of the atrium
A number of stimuli that promotes AF converge in increasing 
expression levels of TGF-β1, which in turn provokes 
interstitial ﬁ  brosis (Figure 3). However, while upregula-
tion of TGF-β1 represents a key event in inducing ﬁ  brosis, 
other growth factors are known to synergize with TGF-β1 
for this effect. For example, connective tissue growth factor 
(CTGF), and platelet-derived growth factor (PDGF). 
Interestingly, while TGF-β1 promotes ﬁ  brosis and increases 
collagen gene expression by acting through Smad proteins 
signaling pathway (Piek et al 1999; Hao et al 2000; Evans 
et al 2003), inhibiting the activity of PI3K reduces TGF-β 
induced EMT, suggesting a role for Smad-independent path-
ways in ﬁ  brosis (Bakin et al 2000). In fact, the p38MAPK 
pathway is also believed to be required for TGF-mediated 
EMT (Bakin et al 2002).
Ang II has been also implicated in promoting the activation 
of fibroblasts, as well as the synthesis of extracellular 
matrix proteins, such as collagen and proteoglycan. 
Additionally, Ang II regulates production of matrix 
metalloproteinases (eg, MMP-2), as well as the breakdown 
of collagen IV (Mehta and Griendling 2007). Interestingly, 
cardiac ﬁ  broblasts exposed to Ang II overexpress both 
ﬁ  bronectin and TGF-β1 (Moriguchi et al 1999). Actually, 
the proﬁ  brotic effects of Ang II are largely explained by its 
ability to increase expression levels of TGF-β1 (Kisseleva 
and Brenner 2008).
There are several differences between atrial and 
ventricular structural remodeling. For example, while at the 
ventricle TGF-β1 provokes hypertrophy, this is prevented by 
TGF-β1 at the atrium (Nakajima et al 2000). Additionally, 
compared to the ventricle, the atrial tissue is more susceptible 
to develop ﬁ  brosis (Nakajima et al 2000; Hanna et al 2004). 
Moreover, leukocyte inﬁ  ltration, cell death, apoptosis and 
MAP kinase activation, are larger in atrium, occur earlier, 
and are more transient in atrium compared to ventricle 
(Hanna et al 2004). In a very interesting study, Burstein 
and colleagues (2008) investigated the different behavior of 
atrial and ventricular ﬁ  broblasts. Basically, they found the 
atrial ﬁ  broblasts show enhanced reactivity, which contributes 
to greater atrial ﬁ  brotic responses. Apparently, a different 
behavior between atrial and ventricular ﬁ  broblasts is due to 
an increased expression of the PDGF receptor in the atrium 
(Burstein et al 2008).
Electrical remodeling
Cardiac excitation-contraction (EC) coupling consists of intra-
cellular Ca2+ release that occurs in response to activation of 
type 2 ryanodine receptors (RyR2s, located at the sarcoplasmic 
reticulum or SR). Intracellular Ca2+ release is triggered by Ca2+ 
entering through voltage dependent Ca2+ channels (L-type Ca2+ 
channels, or L-channels) located at the sarcolemma (termed 
Ca2+ induced Ca2+ release, or CICR) (Fabiato and Fabiato 
1979). This combination of Ca2+ inﬂ  ux and release transiently 
Heart failure Rapid atrial rate 
Fibrosis
TGF-β1
Pseudo
electrical 
remodeling
Electrical remodeling
True
electrical 
remodeling
Atrial fibrillation
A
F
 
b
e
g
e
t
s
 
A
F
Figure 3 Role of TGF-β on atrial remodeling. Certain physiological and 
pathophysiological conditions (ie, heart failure, rapid atrial rate of electrical 
stimulation, aging, and atrial dilatation) promotes the development of atrial ﬁ  bro-
sis, which in turn provokes AF.   Atrial ﬁ  brosis is developed in parallel to increased 
expression of TGF-β1, a well known pro-ﬁ  brogenic agent. Interestingly, a compound 
named pirfenidone that exerts its biological actions by inhibiting the synthesis of 
TGF-β1, also prevents development of both atrial ﬁ  brosis and AF.41 This suggests 
a cause-effect relationship, by which TGF-β1 promotes development of atrial 
ﬁ  brosis, and thereby AF. Recent evidences obtained from cultured cells suggest 
that TGF-β1 also provokes electrical remodeling (Table 1). These potentially in vivo 
electrophysiological effects by TGF-β1 could be attributed to a direct effect on ion 
channels expression and function (dotted arrow). Alternatively, they could be medi-
ated by structural remolding (eg, ﬁ  brosis). Once established, electrical remodeling 
provokes AF and a vicious circle begins – termed atrial ﬁ  brillation begets atrial 
ﬁ  brillation, or AF begets AF.Vascular Health and Risk Management 2008:4(6) 1294
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increases intracellular free Ca2+ concentration (termed Ca2+ 
transient), which in turn activates the contractile machinery. 
The relaxation process occurs following termination of the Ca2+ 
transient, which depends mostly on the removal of cytosolic 
Ca2+ by the activities of: sarco(endo)plasmic reticulum Ca2+-
ATPase (SERCA), sarcolemmal Na+/Ca2+ exchanger (NCX), 
sarcolemmal Ca2+-ATPase, and mitochondrial Ca2+ uniport 
(Bers 2002). Ca2+-dependent inactivation of L-channels, on 
the other hand, guarantees fast termination (in milliseconds) 
of the triggering Ca2+ inﬂ  ux (Bers and Perez-Reyes 1999; 
Catterall 2000).
In addition to L-current (ICaL), cardiac myocytes express 
often a voltage-dependent T-type Ca2+ current (T-current, or 
ICaT) whose physiological relevance remains elusive (Bers and 
Perez-Reyes 1999). Voltage-dependent Na+ channels generate 
also quickly activating inward currents (INa), which are at least 
partially responsible for the fast depolarizing upstroke of the 
action potential (AP) (Balser JR 1999; Clancy and Kass 2005). 
Repolarization, on the other hand, is favored by inactivation of 
inward currents, but depends primarily on the activation of the 
following K+ currents – which are often composed of two or 
more subcomponets: inward rectiﬁ  er (IK1), transient outward 
(Ito), delayed rectiﬁ  er (IKsus), and a time independent background 
current (IKP) (Snyders 1999; Clancy and Kass 2005). Thus, as 
in other excitable cells APs of the cardiac myocytes depend on 
a delicate balance on the activity of several ion channels and 
transporters. Consequently, heart disease is commonly associated 
to several channelopathies, which are not only restricted to 
inherited disorders, but involve also acquired alterations in 
either the expression or post translational modiﬁ  cation of ion 
channels (Clancy and Kass 2005; Tomaselli and Marbán 1999; 
Marbán 2002). The observation that tachyarrhythmias modify 
electrophysiological properties in the same manner as cardiac 
disease has lead to the concept “electrical or electrophysiological 
remodeling” (Figures 2 and 3). However, the precise alterations 
involved in this process, regarding to ion channel function and 
expression remain controversial (Pandozi and Santini 2001).
This is partially due to the different experimental models 
that are commonly used in heart disease. Another source 
of variation is that the alterations change during disease 
progression or transition to failure. In fact, different times of 
exposure to the pathophysiologic substrate may result in either 
“pseudo” (acute) or “true” (chronic) electrical remodeling 
(Figures 2 and 3). Pseudo-remodeling have short onset 
and offset kinetics (minutes), and involve alterations in the 
activity (or functional properties) of a ﬁ  xed number of ion 
channels, transporters, and pumps (Pandozi and Santini 2001). 
In contrast, true electrical remodeling is associated with 
alterations in the expression levels of functional ion channels, 
transporters, and pumps. Accordingly, alterations on 
mRNA levels encoding to these proteins are commonly 
observed. True electrical remodeling has therefore, long 
onset and offset kinetics, last for a long time (hours or days) 
and is not functional or metabolic (Pandozi and Santini 
2001; Allessie 1998).
Electrical remodeling
of the ventricle
Shortenings of action potential duration (APD) and effective 
refractory period (ERP) are typical of atrial ﬁ  brillation 
(see below, Electrical remodeling of the atrium). In contrast, 
rapid rates of stimulation prolong both the APD and the ERP 
at the ventricle. Prolongation of the APD is characteristic of 
ventricular cells and tissues on which heart failure is induced 
by a number of mechanisms, including pressure and vol-
ume overload, genetic, metabolic, ischemia/infarction, and 
chronic pacing tachycardia. In certain models of ventricular 
failure prolongation of the APD is associated, as for the atrial 
myocytes, to reductions in ICaL, Ito, and expression levels of 
the corresponding genes. It is interesting thus that opposite 
alterations in APD can be related to changes in the same 
ionic currents (ICaL and Ito). However, the relative contribu-
tion of these channels to the AP differs substantially between 
atrium and ventricle, and this contributes to explaining the 
differences in APD between the two cavities.
Electrical remodeling of the ventricle also involves a 
parallel reduction in the amplitude and the rate of decay 
of Ca2+ transients, which provokes a reduced capability to 
develop force. Interestingly, while ICaL is reduced in certain 
models of HF, it does not necessarily contribute to explain the 
reduced Ca2+ transients. This is because many reports show 
no change in ICaL in the face of a strong depression of both 
contractions and Ca2+ transients (Kääb et al 1996; Gómez 
et al 1997). Instead, reduction of Ca2+ transients and the con-
sequent contractile dysfunction, are both due to depletion of 
SR Ca2+, which may result from RyR2-dependent Ca2+ leak, 
an increased Ca2+ extrusion through the NCX, or a reduced 
function of SERCA (Bers 2001; Wehrens et al 2005).
Electrophysiological effects
of   TGF-β on the ventricle
The reported effects of TGF-β1 on cardiac electrophysiology 
are summarized on Table 1. Pioneer studies that investigated 
these effects were performed on conﬂ  uent cultures of ven-
tricular myocytes, forming a syncytium (Neylon et al 1994; 
Kimura 1997; Carrillo et al 1998). Roberts and colleagues Vascular Health and Risk Management 2008:4(6) 1295
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(1992) found that a chronic exposure of neonatal rat ven-
tricular myocytes to TGF-β1 increases spontaneous beating 
rate of the syncytium. Conceivable, this effect could be at 
least partially explained by TGF-β1 provoking an increased 
SR Ca2+ content, and a higher frequency of spontaneous 
intracellular Ca2+ oscillations. Accordingly, both of these 
effects were subsequently reported by Neylon and colleagues 
(1994). More recently, Carrillo and colleagues (1998) reported 
that the increase in beating rate is also associated to a higher 
expression of the Na+/Ca2+ exchanger, which could prepare 
cells to deal better with the Ca2+ overload associated to high 
frequency of Ca2+ oscillations. While these studies support the 
notion that TGF-β1 increases beating rate of the syncytium, 
Kimura (1997) reported an opposite effect, which was asso-
ciated to an increased IP3-sensitive intracellular Ca2+ store. 
Currently, molecular bases for this apparent contradiction 
remain unknown.
To our knowledge, only one study has investigated the 
electrophysiological effects of TGF-β1 in adult ventricular 
myocytes (Roberts et al 1992). What these authors found 
is that ∼4 h of exposure to TGF-β1 provokes “contractile 
dysfunction”, characterized by a signiﬁ  cant reduction on the 
maximum rate of myocyte shortening and re-lengthening. 
Additionally, TGF-β1 reduces the time to peak and the 
rate of decay of intracellular Ca2+ transients, in the absence 
of signiﬁ  cant alterations on ICaL. Molecular mechanisms 
underlying these effects point to an enhanced reactive oxide 
species (ROS) production. However, downstream molecules 
other than ROS have yet to be elucidated.
For instance, the absence of alterations on ICaL could 
be interpreted to suggest that contractile dysfunction and 
effects on Ca2+ transients could both arise from a possible 
regulation on the Ca2+ handling proteins of the SR. However, 
neither the SR Ca2+ content nor spark properties (frequency 
and amplitude) were altered by TGF-β1, even thought this 
factor reduced the phosphorylation state of phospholam-
ban, which in turn modulates SERCA. We should keep in 
mind that ICaL was recorded under whole-cell patch clamp 
conditions, whereas estimations of mechanical proper-
ties and intracellular Ca2+ were performed in intact (ie, 
nonpatched) myocytes (Li et al 2008). This represents an 
important limitation, since misleading conclusions can 
be drawn from comparing results of different conditions. 
For example, intracellular Ca2+ can be strongly inﬂ  uenced 
Table 1 Modulation of cardiac electrophysiology by TGF-β1
Preparation Results References
Ventricle
Cultured neonatal rat myocytes A chronic exposure (48 h) to TGF-β1 increases 
the frequency of spontaneous Ca2+ oscillations, 
and increases the caffeine-sensitive intracellular 
Ca2+ store
Neylon et al 199471
Cultured neonatal rat myocytes In ∼4 d TGF-β1 moderately (16%) decreases the 
spontaneous beating rate and increases the IP3-
sensitive intracellular Ca2+ store
Kimura et al 199773
Cultured neonatal rat myocytes TGF-β1 increases in 24 h both beating rate and 
expression levels of mRNA encoding the Na+/Ca2+ 
exchanger
Carrillo et al 199772
Cultured adult rat myocytes TGF-β1 decreases in ∼4 h the rate of myocyte 
shortening and relaxation, delays the peak of Ca2+ 
transients, and slows its rate of decay (termed 
“contractile dysfunction”)
Li et al 200875
Atria
Atrial tissue from TGF-β1 overexpressing mice TGF-β1 overexpression provokes vulnerability to 
atrial ﬁ  brillation and decreases epicardial conduc-
tion velocity
Verheule et al 200446
Neonatal rat myocytes TGF-β1 reduces in 1–2 d ICaL, nifedipine-sensitive 
charge movement, and expression levels of CaV1.2 
mRNA
Avila et al 200787
Neonatal rat myocytes TGF-β1 chronically (1–2 d) reduces current 
densities associated to INa, IK1, and IKsus
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by dialysis of the cytosol under whole-cell patch-clamp 
conditions. Finally, we should keep in mind that these data 
were obtained in cultured myocytes and the situation may 
be different in vivo.
Electrical remodeling of the atrium
An important step toward understanding atrial ﬁ  brillation 
(AF) was the discovery that once initiated, AF alters atrial 
electrical properties, in a manner that favors the maintaining 
of the arrhythmia (ie, electrical remodeling, as a vicious 
circle (Wijffels et al 1995)). Initially, high frequencies of 
atrial activation (ie, rapid atrial rate; Figure 3) leads to what 
is known as a short-term APD (action potential duration) 
adaptation to rate, which is due to rapid (minutes) functional 
changes in ion channels and transporters (basically, what 
happens is that at high frequencies of stimulation, the atrium 
responds with a shortening of the APD). Thus, rapid atrial 
rate stimulation provokes “pseudo” electrical remodeling 
(Figure 3).
This short-term adaptation can be at least partially 
explained by an increase in Ca2+-dependent inactivation of 
ICaL(Yagi et al 2002). Accordingly, cytosolic Ca2+ overload 
is also involved, which may activate intracellular signaling 
pathways that play a prominent role in the subsequent “true” 
electrical remodeling (Nattel 1999). Following this short-term 
adaptation, the atrial tachycardia begins to produce discrete 
changes in the expression levels of speciﬁ  c genes (in hours 
or days). Speciﬁ  cally, the proteins or mRNAs encoding to the 
principal subunits of ICaL(Yue et al 1999; Brundel et al 2001), 
(but see Brundel and colleagues [Christ et al 2004]), INa (Yue 
et al 1999), IKur (Lai et al 1999), and Ito (Yue et al 1999) are 
downregulated, whereas the corresponding subunits of IK1 and 
IK,Ach are upregulated (Dobrev et al 2001; Gaborit et al 2005) 
in a similar time-course and magnitude as the corresponding 
ionic currents (Pandozi and Santini 2001; Allessie 1998; Nattel 
et al 2007; Nattel et al 2008).
True ionic remodeling (ie, changes in ion channel 
expression) permanently reduce the APD, the capability 
of APD to adapt to rate, and the effective refractory period 
(ERP). Altogether, these changes give rise to a vicious circle 
(Figure 3). This is because decrease ERP promotes AF, by 
decreasing the wavelength (distance traveled by the electrical 
wave during the ERP, which determines the minimum path 
length that can support electrical reentry). This in turn allows 
the atrium to accommodate a larger number of reentry 
circuits, decreasing the chance of spontaneous termination. 
Thus, ionic remodeling can be seen as a protective 
mechanism against the initial Ca2+ overload. However, the 
protective effect occurs at the expense of promoting the 
maintenance of AF, which nonetheless eventually alters Ca2+ 
homeostasis (Nattel et al 2008).
Effects of TGF-β on electrical 
remodeling of the atrium
An interesting effect of TGF-β1 is that it can provoke 
an increased susceptibility to develop atrial ﬁ  brillation. 
This was discovered in 2004 by Verheule and colleagues 
(2004), using transgenic mice overexpressing cardiac 
TGF-β1. These animals also present a decreased epicar-
dial conduction velocity on the right atria, as well as a 
more heterogeneous conduction on the left atria. Since 
no differences in action potential properties were found, 
Verheule and colleagues (2004) concluded that atrial 
ﬁ  brosis induced by TGF-β1 is sufﬁ  cient to enhance the 
inducibility of AF (as opposed to electrical remodeling) 
(2004). Unfortunately, they did not investigate ICaL or a 
potential loss of the capability of APs to adapt to high rate 
of stimulation, which would have suggested alterations on 
ICaL. In keeping with this possibility, we have previously 
reported that TGF-β1 reduces expression levels of ICaL, 
in neonatal rat atrial myocytes (Avila et al 2007). More-
over, in these cells TGF-β1 also reduces current densities 
associated to INa, IKsus, and IK1 (Ramos-Mondragón 2008). 
Thus, at least in cardiomyocytes from neonatal rat 
TGF-β1 reproduces electrophysiological alterations that 
are commonly seen in AF.
Molecular bases for downregulation of ICaL by TGF-β1 
point to a decreased expression of mRNA encoding to 
CaV1.2, the principal subunit of L-type Ca2+ channels. 
Accordingly, TGF-β1 also provokes reduction in the 
amount of immobilization-resistant charge movement, 
which reflects voltage sensor’s activity of CaV1.2. 
Moreover, inhibition of ICaL by TGF-β1 cannot be reverted 
by okadaic acid, an inhibitor of protein phosphatases, 
supporting the notion that this effect is not due to a possible 
reduction in the permanent phosphorylation state of the 
channels (Avila et al 2007).
As previously discussed (see Electrical remodeling of 
the atrium), molecular mechanisms underlying reduction 
of ICaL in AF include an altered function of CaV1.2. For 
example, ICaL is functionally reduced in AF by at the least 
the following mechanisms: 1) Ca2+-dependent inactiva-
tion (Yagi et al 2002). 2) Reduced phosphorylation state 
due to either increased activity of protein phosphatases 
(Christ et al 2004), or impaired regulation by src kinase Vascular Health and Risk Management 2008:4(6) 1297
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(Greiser et al 2007). 3) Increased S-nitrosylation, due to 
decreased expression of the antioxidant glutation (Carnes 
et al 2007). Remarkably, ICaL reduction has been also attrib-
uted to reduced expression levels of CaV1.2.(Yue et al 1999; 
Brundel et al 2001).
The question of whether TGF-β1 actually regulates ICaL 
in adult atrial myocytes still remains to be solved. A recent 
study suggests increased in vivo levels of TGF-βs (in 
AF induced by rapid atrial pacing) do not significantly 
alter expression levels of CaV1.2 (Chen et al 2007). 
In contrast, the following evidences suggest possible 
functional effects. TGF-β1 increases intracellular levels 
of reactive oxide species (ROS) in adult ventricular myo-
cytes (Li et al 2008). On the other hand, increased ROS 
levels can provoke a reduced density of ICaL in adult atrial 
myocytes (Carnes et al 2007). Thus, conceivable, in adult 
atrial myocytes TGF-β1 could decrease ICaL, by means of 
increasing levels of ROS. Undoubtedly, this possibility 
deserves to be elucidated.
Perspectives
Recently, arrythmogenic right ventricular dysplasia type 1 
(ARVD1) was associated to mutations in the gene encoding 
TGF-β3 (Beffagna et al 2005). ARVD1 is a progressive 
myocardial disease characterized by ventricular arrhythmias 
that lead to sudden unexpected death. The reported muta-
tions increase expression levels of TGF-β3, which might 
in turn provoke the arrhythmia by promoting ﬁ  brosis and 
electrophysiological effects. In 2000, Brooks and Conrad 
(Brooks and Conrad 2000) reported that senescent animals 
from TGF-β1 heterozygous (±) mice exhibit a decreased 
amount of myocardial fibrosis compared to controls. 
Additionally, these mice develop increased left ventricu-
lar compliance, live longer, and do not present a normal 
increase in diastolic pressure. This suggests decreased levels 
of the growth factor by loss of one TGF-β1 allele prevents 
development of myocardial stiffness induced by ﬁ  brosis. 
Alternatively, decreased levels of TGF-β1 in heterozygous 
(±) mice could also prevent development of a possible nor-
mal “contractile dysfunction” in senescent animals, similar 
to the electrophysiological effects that TGF-β1 exerts on 
cultured adult ventricular myocytes (Roberts et al 1992), 
see also Table 1.
On the other hand, Kubin and colleagues (2005) reported 
that in the absence of serum TGF-β1 reduces in 6 days the 
beating rate of adult rat ventricular myocytes, but does not 
alter the corresponding morphological properties. Thus, 
it will be interesting to investigate a possible relationship 
between the acute contractile dysfunction (Roberts et al 
1992), and the chronic decrease in beating rate (Kubin et al 
2005).
There are a number of unanswered questions regarding 
electrophysiological effects by TGF-β. To this date only the 
type 1 TGFβ has been used to perform electrophysiological 
studies (see Table 1). However, there are numerous of 
noncompensated functions among the three isoforms of 
the TGF-β subfamily (see the section role of TGF-β in 
cardiac development). An interesting prediction would 
be that different TGF-βs preferentially regulate speciﬁ  c 
regions of the heart. Support to this view comes from the 
fact that TGF-β1 exerts opposite effects on atrial and ven-
tricular hypertrophy (inhibition and stimulation, respectively 
(Nakajima et al 2000)). Moreover, while transgenic mice 
overexpressing TGF-β1 develop increased vulnerability to 
atrial ﬁ  brillation (Verheule et al 2004), mutations in the gene 
encoding TGF-β3 are linked to a genetically determined 
myocardial dystrophy (ie, arrythmogenic right ventricular 
dysplasia type 1 or ARVD1 (Beffagna et al 2005)). TGF-
β2, on the other hand, is preferentially involved in mitral 
valve disease (Ng et al 2004) and certain cardiovascular 
anomalies (Sandford et al 1997; Bartram 2001). Thus, we 
anticipate elucidating effects of the two other isoforms will 
be of paramount relevance.
The beneﬁ  cial effects of certain neurohumoral blockers 
on cardiac disease can be at least partially explained by 
their ability to inhibit electrical remodeling (Katz 2002; 
Nattel 2002; Shinagawa et al 2003). Nevertheless, while 
certain drugs can be successfully used for the treatment 
of atrial ﬁ  brillation, they often result in potentially lethal 
alterations on ventricular electrophysiology. These 
opposite effects could be potentially explained by the 
aforementioned differences in electrical remodeling of the 
atrium and the ventricle. Thus, the identiﬁ  cation of factors 
that selectively control ion channel expression and function 
in atrial vs ventricular myocytes, could be advantageous to 
ﬁ  nd a more effective treatment of cardiac disease.
In conclusion, it has been recognized during the last 
20 years that TGF-β plays a critical role in cardiac disease. 
Accordingly, signiﬁ  cant efforts are been currently made to 
discover potential therapeutic roles for TGF-β signaling in 
cardiac pathology.(Li et al 2005; Narine et al 2004; Ng et al 
2004; Liao 2005; Okada et al 2005). Thus, we believe that 
unraveling the corresponding electrophysiological effects 
may contribute to improve the clinical use of TGF-β-related 
agents, by providing the grounds for more rational and 
speciﬁ  c therapies.Vascular Health and Risk Management 2008:4(6) 1298
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